Fig. 5.
![Fig. 5. Effects of group I antagonists on the second [Ca2+]i peak in thrombasthenic platelets. Platelets obtained from a patient with Glanzmann thrombathenia were preincubated with 10 μmol/L of each group I antagonist and then stimulated with 0.03 U/mL thrombin. (A) None. (B) FK633. (C) FR169824.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/92/10/10.1182_blood.v92.10.3675/4/blod42238005x.jpeg?Expires=1724257289&Signature=yd0X4ox4Fo1H99r0YPYi6my3iSBYG9AcWoN2WXbRxxerhqDnYVg08dvVrDC1FfAQJxvjoo0k3p8jKaeTaM0M8nGijTbneE9BAsh27LFdOHAzk~QCT3VPFHIemaQs5dWgN5d1V~ujlGJwbeMPEhrCSXhPMGKPF~UsE2SgMnsyOHbJaPOPuQWh3q5uG~Bpf-PqXkf6OLweudOYYApO~fUXj5eI6CbAm1l88wf-CpwNuOklATrNvpG8LJmj9yI-r~btF6jtJtTqdmVZ1X3LkYWfLKCoufgfxZj5TzNtRFeikXSoCKKCrpISWV17HOfLms38Ql7jSPiYxEq65TP12TnQug__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Effects of group I antagonists on the second [Ca2+]i peak in thrombasthenic platelets. Platelets obtained from a patient with Glanzmann thrombathenia were preincubated with 10 μmol/L of each group I antagonist and then stimulated with 0.03 U/mL thrombin. (A) None. (B) FK633. (C) FR169824.
